Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Update

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the target of a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 31,149 shares, an increase of 119.7% from the June 15th total of 14,178 shares. Based on an average trading volume of 137,032 shares, the short-interest ratio is presently 0.2 days. Currently, 0.6% of the shares of the company are sold short.

Redhill Biopharma Trading Down 1.6%

Shares of NASDAQ RDHL traded down $0.01 during trading on Thursday, reaching $0.73. 11,796 shares of the company traded hands, compared to its average volume of 318,798. The firm’s fifty day simple moving average is $0.89 and its 200 day simple moving average is $0.97. The stock has a market cap of $4.44 million, a P/E ratio of 0.00 and a beta of 4.98. Redhill Biopharma has a 12-month low of $0.64 and a 12-month high of $3.31.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Redhill Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Redhill Biopharma has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Redhill Biopharma stock. Gagnon Securities LLC raised its stake in Redhill Biopharma Ltd. (NASDAQ:RDHL) by 383.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 86,102 shares of the biotechnology company’s stock after acquiring an additional 68,280 shares during the quarter. Gagnon Securities LLC owned approximately 1.68% of Redhill Biopharma worth $89,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.20% of the company’s stock.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.